{"nctId":"NCT02793817","briefTitle":"Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain","startDateStruct":{"date":"2016-06","type":"ACTUAL"},"conditions":["Post Surgical Ocular Inflammation and Pain"],"count":520,"armGroups":[{"label":"KPI-121 1.0% Ophthalmic Suspension","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: KPI-121 1% Ophthalmic Suspension dosed BID"]},{"label":"Vehicle of KPI-121 Ophthalmic Suspension","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID"]}],"interventions":[{"name":"KPI-121 1% Ophthalmic Suspension dosed BID","otherNames":["Loteprednol etabonate"]},{"name":"Vehicle of KPI-121 Ophthalmic Suspension dosed BID","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nCandidates for routine, uncomplicated cataract surgery\n\nIn Investigator's opinion, potential postoperative Snellen Distance VA by pinhole method of at least 20/200 in study eye.\n\nExclusion Criteria:\n\n* Known hypersensitivity/contraindication to study product(s) or components.\n* History of glaucoma, intraocular pressure (IOP) \\>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.\n* Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; severe/serious systemic disease or uncontrolled medical condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within the 30 days prior to screening or 18 days following surgery.\n* In the opinion of Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Resolution of Anterior Chamber (AC) Cells at Day 8","description":"Number and percentage of subjects with complete resolution of AC cells in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.\n\nInvestigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.\n\nAnterior Chamber Cells 0 = No cells seen\n\n1. = 1 - 5 cells\n2. = 6 - 15 cells\n3. = 16 - 30 cells\n4. = greater than 30 cells","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"PRIMARY","title":"Complete Resolution of Ocular Pain at Day 8","description":"Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 8 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.\n\nSubjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes.\n\nThe following scoring scale was used for ocular pain:\n\n0 = None\n\n1. = Minimal\n2. = Mild\n3. = Moderate\n4. = Moderately Severe\n5. = Severe","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Resolution of Ocular Pain at Day 4","description":"Number and percentage of subjects with complete resolution of ocular pain in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.\n\nSubjects were given the Subject-Rated Ocular Pain Assessment to subjectively rate their pain at Days 1, 4, 8, 15, and the follow-up visit between Days 17 and 19. Higher scores were worse outcomes.\n\nThe following scoring scale was used for ocular pain:\n\n0 = None\n\n1. = Minimal\n2. = Mild\n3. = Moderate\n4. = Moderately Severe\n5. = Severe","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Resolution of Anterior Chamber (AC) Flare at Day 4","description":"Number and percentage of subjects with complete resolution of AC flare in the surgical eye (study eye) at Day 4 maintained through Day 15, without receiving rescue medication prior to Day 15, for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.\n\nInvestigators were asked to grade AC flare based on the following scale wherein higher scores indicate a higher degree of flare present and a decrease across time indicates the condition is getting better.\n\nAnterior Chamber Flare 0 = None\n\n1. = Mild (trace to clearly noticeable, visible)\n2. = Moderate (without plastic aqueous humor)\n3. = Marked (with plastic aqueous humor)\n4. = Severe (with fibrin deposits and/or clots)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 4","description":"The difference in mean changes from BL in AC cell count grade at Day 4 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.\n\nInvestigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.\n\nAnterior Chamber Cells 0 = No cells seen\n\n1. = 1 - 5 cells\n2. = 6 - 15 cells\n3. = 16 - 30 cells\n4. = greater than 30 cells","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.84"},{"groupId":"OG001","value":"-0.5","spread":"0.91"}]}]}]},{"type":"POST_HOC","title":"Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 8","description":"The difference in mean changes from BL in AC cell count grade at Day 8 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.\n\nInvestigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.\n\nAnterior Chamber Cells 0 = No cells seen\n\n1. = 1 - 5 cells\n2. = 6 - 15 cells\n3. = 16 - 30 cells\n4. = greater than 30 cells","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"0.90"},{"groupId":"OG001","value":"-1.0","spread":"0.94"}]}]}]},{"type":"POST_HOC","title":"Change From Baseline (BL) Anterior Chamber (AC) Cells at Day 15","description":"The difference in mean changes from BL in AC cell count grade at Day 15 for KPI-121 1% dosed twice daily (BID) compared with vehicle dosed BID.\n\nInvestigators were asked to grade AC cell based on the following scale wherein higher scores indicate a higher degree of cells present and a decrease across time indicates the condition is getting better.\n\nAnterior Chamber Cells 0 = No cells seen\n\n1. = 1 - 5 cells\n2. = 6 - 15 cells\n3. = 16 - 30 cells\n4. = greater than 30 cells","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.84"},{"groupId":"OG001","value":"-1.6","spread":"0.87"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":261},"commonTop":["Eye pain","Headache","Posterior capsule opacification","Cystoid macular oedema","Nasopharyngitis"]}}}